229 related articles for article (PubMed ID: 26344798)
1. The European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry: long-term benefits for breast cancer treatment.
Jerusalem G; Moonen M; Freres P; Lancellotti P
Future Oncol; 2015; 11(20):2791-4. PubMed ID: 26344798
[No Abstract] [Full Text] [Related]
2. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Bird BR; Swain SM
Clin Cancer Res; 2008 Jan; 14(1):14-24. PubMed ID: 18172247
[TBL] [Abstract][Full Text] [Related]
3. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.
Lancellotti P; Anker SD; Donal E; Edvardsen T; Popescu BA; Farmakis D; Filippatos G; Habib G; Maggioni AP; Jerusalem G; Galderisi M
Eur Heart J Cardiovasc Imaging; 2015 May; 16(5):466-70. PubMed ID: 25744342
[TBL] [Abstract][Full Text] [Related]
4. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
5. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?
Caron J; Nohria A
Curr Oncol Rep; 2018 Jun; 20(8):61. PubMed ID: 29876677
[TBL] [Abstract][Full Text] [Related]
7. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of Contemporary Breast Cancer Treatments.
Lee Chuy K; Yu AF
Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
[TBL] [Abstract][Full Text] [Related]
9. Update on cardiotoxicity of anti-cancer treatments.
Rosa GM; Gigli L; Tagliasacchi MI; Di Iorio C; Carbone F; Nencioni A; Montecucco F; Brunelli C
Eur J Clin Invest; 2016 Mar; 46(3):264-84. PubMed ID: 26728634
[TBL] [Abstract][Full Text] [Related]
10. Heart failure and chemotherapeutic agents.
Piper S; McDonagh T
Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
[TBL] [Abstract][Full Text] [Related]
11. Cardio-oncology: Understanding cardiotoxicity to guide patient focused imaging.
Russell R
J Nucl Cardiol; 2018 Dec; 25(6):2159-2167. PubMed ID: 30443750
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
14. Management of Cardiovascular Disease in Women With Breast Cancer.
Barish R; Lynce F; Unger K; Barac A
Circulation; 2019 Feb; 139(8):1110-1120. PubMed ID: 30779651
[TBL] [Abstract][Full Text] [Related]
15. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
16. [What should a cardiologist know about the follow-up and management of a woman with breast cancer ?].
Jagu A
Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):304-308. PubMed ID: 36075766
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
Fiúza M
Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
19. Organization and implementation of a cardio-oncology program.
Fiuza M; Ribeiro L; Magalhães A; Sousa AR; Nobre Menezes M; Jorge M; Costa L; Pinto FJ
Rev Port Cardiol; 2016 Sep; 35(9):485-94. PubMed ID: 27503589
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity: anthracyclines and long term cancer survivors.
Patanè S
Int J Cardiol; 2014 Oct; 176(3):1326-8. PubMed ID: 25129289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
